Abstracts tagged "Inflammation"

Abstract Number: 2839 • 2014 ACR/ARHP Annual Meeting
BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation
Kichul Ko¹, Denisse Yanez¹, Natalya Kaverina¹, Vladimir M. Liarski¹, Yahui Peng², Li Lan³, Stuart Perper⁴, Annette Schwartz⁵, Liz O'connor⁶, Andrew Souers⁷, Steven Elmore⁷, Lisa Olson⁵, Maryellen L. Giger³, Li Chun Wang⁴ and Marcus R. Clark¹, ¹Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, ²School of Electronic and Information Engineering, Beijing Jiaotong University, Beijing, China, ³Radiology, University of Chicago, Chicago, IL, ⁴Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁶Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁷AbbVie Inc, North Chicago, IL
Background/Purpose Lupus nephritis (LuN) is the most common, severe manifestation of systemic lupus erythematosus (SLE). We have previously shown that glomerulonephritis appears to be a…
Abstract Number: 1815 • 2014 ACR/ARHP Annual Meeting
STAT3-Mediated Regulation of Mitochondrial Membrane Potential Is Critical for NLRP3 Inflammasome Activation
Jehad H. Edwan¹, Raphaela Goldbach-Mansky² and Robert A. Colbert³, ¹NIAMS NIH, Bethesda, MD, ²NIAMS, NIH Building 10 Room 6D47B, Bethesda, MD, ³NIAMS/NIH, Bethesda, MD
Background/Purpose: Self-activating mutations in NLRP3 cause a spectrum of autoinflammatory diseases known as cryopyrin-associated periodic syndromes (CAPS). NLRP3 is a key component of a multiprotein…
Abstract Number: 597 • 2014 ACR/ARHP Annual Meeting
Inflammatory Burden in Recent-Onset Axial Spondyloarthritis
Juan Jose Aznar Sánchez¹, Raul Veroz Gonzalez¹, Adela Gallego Flores¹, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez² and Eugenio Chamizo Carmona¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Mérida, Spain
Background/Purpose Patients with Non-Radiographic Axial Spondylarthritis (non-Rx AxSpA) don't presnt with different clinical manifestations than patients with Ankilosing Spondylitis (AS), although the inflammatory burden measured…
Abstract Number: 2822 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Edward C. Keystone¹, Peter C. Taylor², Mark C Genovese³, Douglas E. Schlichting⁴, Inmaculada De La Torre⁵, Scott D. Beattie⁴ and Terence Rooney⁴, ¹University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵AVDA. DE LA INDUSTRIA 30, Eli Lilly and Company, Alcobendas, Spain
Background/Purpose: Baricitinib is an oral inhibitor of JAK1/JAK2 being investigated as a treatment for rheumatoid arthritis (RA). In a phase 2b study, baricitinib treatment resulted…
Abstract Number: 1812 • 2014 ACR/ARHP Annual Meeting
Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome
Yin Liu¹, Adriana Almeida de Jesus^2,3, Bernadette Marrero⁴, Dan Yang⁵, Gina A. Montealegre Sanchez⁶, Steve Brooks⁷, Zuoming Deng⁸, Amy Paller⁹, Manfred Boehm⁵ and Raphaela Goldbach-Mansky⁶, ¹Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Translational Autoinflammatory Diseases Section, NIAMS/NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, ⁵Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁶Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD, ⁸Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁹Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: We have recently studied a group of patients with a prominent interferon (IFN) signature in the blood, distinct from IL-1 mediated autoinflammatory diseases. Six…
Abstract Number: 405 • 2014 ACR/ARHP Annual Meeting
14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴, Kelly Young⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Rheumatoid Patient Foundation, Cocoa, FL, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose In RA, irreversible joint damage often begins within the first year of symptom onset. A compelling and growing body of data describing the "uncoupling"…
Abstract Number: 2792 • 2014 ACR/ARHP Annual Meeting
Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a_2A Receptor (A2AR)
Aranzazu Mediero¹, Tuere Wilder² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Prior studies demonstrate that adenosine, acting at A2AR, mediates the anti-inflammatory effects of methotrexate (MTX) in models of both acute and chronic inflammation. We…
Abstract Number: 1723 • 2014 ACR/ARHP Annual Meeting
Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies
Michael Johnson¹, Zhenghui Li¹, Michelle Dimon², Tammara A. Wood¹, Robert Lafyatis³, Sarah Arron² and Michael Whitfield⁴, ¹Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dermatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Center, Boston University, Boston, MA, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare and poorly understood systemic autoimmune disease that results in skin fibrosis and severe internal organ involvement. There…
Abstract Number: 344 • 2014 ACR/ARHP Annual Meeting
Reduced Macrophages in the Synovium Contribute to the Effective Treatment of Spontanneous Arthritis Observeded in Human TNF-Transgenic Mice
Robert Birkett¹, Qi Quan Huang¹, Bo Shi² and Richard Pope³, ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ³Medicine/Rheumatology Div, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose Macrophages in rheumatoid arthritis (RA) synovial tissue (ST) produce high levels of inflammatory cytokines/chemokines and exhibit enhanced differentiation into osteoclasts in the pannus, playing…
Abstract Number: 2433 • 2014 ACR/ARHP Annual Meeting
Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Fabiola Atzeni^1,2, Alessandra Monguzzi³, Elisabetta Grillo³, Luigi Lanata³ and Piercarlo Sarzi-Puttini², ¹V Giovanni Battista Grassi 74, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ²Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ³Medical Department, Dompé SpA, Milan, Italy
Background/Purpose: Patients with rheumatic diseases, including rheumatoid arthritis (RA), describe symptoms such as pain and stiffness as important factors affecting their quality of life. The…
Abstract Number: 1643 • 2014 ACR/ARHP Annual Meeting
Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose Systemic lupus erythematosus (SLE) presents with a wide spectrum of clinical and immunologic abnormalities. On the other hand, exciting data is emerging about the…
Abstract Number: 35 • 2014 ACR/ARHP Annual Meeting
Hydrogen Sulfide Inhibits Human Osteoclast Differentiation in Vitro By Triggering Sustained Antioxidant Response and Inhibiting the RANKL/OPG Ratio
Francesco Grassi¹, Laura Gambari², Andrea Facchini³ and Gina Lisignoli⁴, ¹LAB. RAMSES, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, ²Lab. RAMSES, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, ³Lab of Immunorheumatology and Tissue Regeneration, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy, ⁴LAB. OF IMMUNORHEUMATOLOGY AND TISSUE REGENERATION, ISTITUTO ORTOPEDICO RIZZOLI, BOLOGNA, Italy
Background/Purpose Hydrogen sulfide (H2S) has been recently appreciated as a novel gasotransmitter with an important role in the regulation of tissues and organs. H2S is…
Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting
Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis
Aziza Elmesmari¹, Derek G. Gilchrist², Mariola Kurowska-Stolarska³ and Iain B. McInnes⁴, ¹Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span. MicroRNA 155 (miR155) is particularly implicated in…
Abstract Number: 1516 • 2014 ACR/ARHP Annual Meeting
TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis
Marlene Andersen¹, Michael Kruse Meyer², Ivan Nagaev³, Olga Nagaeva³, Jarl E.S. Wikberg⁴, Lucia Mincheva-Nilsson³ and Grethe N. Andersen², ¹Department of Rheumatology, Aalborg University, Hjørring, Denmark, ²Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ³Department of Clinical Immunology, University of Umeå, Umeå, Sweden, ⁴Department of Pharmaceutical Biosciences, Department of Pharmaceutical Pharmacology, Uppsala, Sweden
Background/Purpose: We examined Adalimumab´s effects on melanocortin receptor subtype (MC)1-5 gene expression in important leukocyte subsets in rheumatoid arthritis (RA). The melanocortin system is a…
Abstract Number: 33 • 2014 ACR/ARHP Annual Meeting
Stimulation of the Adenosine a_2Areceptor (A2AR) Regulates the Expression of Netrin1 and Their Receptors (Unc5b, DCC) and Inhibits Osteoclast Differentiation and Inflammatory Bone Destruction
Aranzazu Mediero¹, Bhama Ramkhelawon², Miguel Perez-Aso³, Kathryn Moore² and Bruce N. Cronstein⁴, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, ³545 1st Ave., New York University, New York City, NY, ⁴NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose A variety of molecules mediate communication between osteoclasts and osteoblasts during bone remodeling. Netrin1 is a member of the family of axonal guidance proteins,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].